Andrew S Poklepovic, Sarah W Gordon, Sejal Kothadia, William P McGuire, Leroy R Thacker, Xiaoyan Deng, Mary Beth Tombes, Ellen Shrader, Daniel Hudson, Dipankar Bandyopadhyay, Alison A Ryan, Maciej Kmieciak, Steven Smith, Paul Dent
The purpose of this study is to establish the recommended phase 2 dose for regorafenib in combination with sildenafil for patients with advanced solid tumors. Secondary outcomes included identification of antitumor effects of regorafenib and sildenafil, toxicity of the combination, determination of PDE5 expression in tumor samples, and the impact of sildenafil on the pharmacokinetics of regorafenib. This study was a phase 1, open-label single-arm dose-escalation trial using a 3 + 3 design. Additional patients were enrolled at the maximum tolerated dose (MTD) until a total of 12 patients were treated at the MTD...
March 8, 2024: Anti-cancer Drugs